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Background: Biological augmentation of rotator cuff repair is of growing interest to improve biomechanical properties
and prevent re-tearing. But intraoperative single shot growth factor application appears not sufficient to provide healing
support in the physiologic growth factor expression peaks. The purpose of this study was to establish a sustained release
of granulocyte-colony stimulating factor (G-CSF) from injectable vesicular phospholipid gels (VPGs) in vitro and to examine
biocompatibility and influence on histology and biomechanical behavior of G-CSF loaded VPGs in a chronic supraspinatus
tear rat model.
Methods: G-CSF loaded VPGs were produced by dual asymmetric centrifugation. In vitro the integrity, stability and
release rate were analyzed. In vivo supraspinatus tendons of 60 rats were detached and after 3 weeks a transosseous
refixation with G-CSF loaded VPGs augmentation (n = 15; control, placebo, 1 and 10 μg G-CSF/d) was performed. 6 weeks
postoperatively the healing site was analyzed histologically (n = 9; H&E by modified MOVIN score/Collagen I/III) and
biomechanically (n = 6).
Results: In vitro testing revealed stable proteins after centrifugation and a continuous G-CSF release of up to 4 weeks.
Placebo VPGs showed histologically no negative side effects on the healing process. Histologically in vivo testing
demonstrated significant advantages for G-CSF 1 μg/d but not for G-CSF 10 μg/d in Collagen III content (p = 0.035)
and a higher Collagen I/III ratio compared to the other groups. Biomechanically G-CSF 1 μg/d revealed a significant
higher load to failure ratio (p = 0.020) compared to control but no significant differences in stiffness.
Conclusions: By use of VPGs a continuous growth factor release could be obtained in vitro. The in vivo results
demonstrate an improvement of immunohistology and biomechanical properties with a low dose G-CSF application
via VPG. The VPG itself was well tolerated and had no negative influence on the healing behavior. Due to the favorable
properties (highly adhesive, injectable, biocompatible) VPGs are a very interesting option for biologic augmentation.
The study may serve as basis for further research in growth factor application models.
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Rotator cuff tears are a common cause of shoulder pain,
reduced function and weakness of the arm in the elderly
patient [1]. The retear rate still ranges between 25% and
94%, despite biomechanically proven stability of the pri-
mary tendon reinsertion [2-5]. Besides individual patient
factors like age, tear size and tendon-/muscle quality the
biological healing response is identified as essential fac-
tor to improve tendon healing [6]. Therefore current
research is focusing on the use of growth factors (GF)
for biological augmentation [7]. Although a number of
studies using growth factors have been published they
mostly used a single injection or a single intraoperative
application at time zero. The reported limited success
might be due to their very short in vivo half-life time
and the previously described GF peak expression in ten-
don healing which is GF dependent between day 7 and
14 after injury [8,9]. To gain this biological activity at
their physiological peak expression multiple GF injec-
tions or sustained GF release from a carrier is required.
Multiple injections are invasive and include the risk of
variation of the application site so that the sustained re-
lease remains a valuable option.
A previous study has shown that continuous release of
G-CSF via an osmotic pump positively affected the
supraspinatus tendon (SSP) remodeling in a chronic SSP
tear rat model [10]. Nevertheless, the rate of pump dislo-
cations (30%) and the invasiveness of the surgical pro-
cedure (subcutaneous pump implantation as foreign
body and additional subacromial tube) were seen as sig-
nificant disadvantages compromising the results ob-
tained and can only be considered as a preclinical tool
to establish the proof of principle. This led to the idea of
an injectable vesicular phospholipid gel (VPGs) as a car-
rier for GF delivery. These gels are composed of non-
toxic excipients, namely lecithin and aqueous buffer
solution and show an excellent biocompatibility. The
formulations are very robust and easy to produce, but
allow on the other hand a burst free, continuous release
of GFs over days and weeks, depending on their specific
composition and the nature of the incorporated drug
[11,12]. The easy application of such semi-solid, oint-
ment like gels in open and also arthroscopic surgery, as
well as the adaptation to different surface modalities due
to the tunable mechanical properties of the gel formula-
tion can be seen as further advantages. In vitro studies
revealed the feasibility of continuous erythropoietin
(EPO) release via such vesicular phospholipid gels over
more than 400 h [13].
The purpose of the present study was to evaluate the
in vitro release kinematics of G-CSF by phospholipid
gels and in the following to examine the effect of con-
tinuous G-CSF release via phospholipid gels on tendon
remodeling in a chronic supraspinatus tear rat model.According to the purpose of the study we evaluated
the hypothesis that a continuous G-CSF release by
phospholipid gels could be achieved and that the appli-
cation of G-CSF loaded VPGs as biological augmenta-
tion in a chronic supraspinatus rat model results in a
significant improvement of histological and biomechan-
ical healing properties.Methods
In a first step, the aim was to evaluate in vitro the best
combination of the gel’s release properties and viscosity
for optimized intraoperative handling, therefore different
variation of pH, G-CSF and lipid content were analyzed.
Second the in-vivo effects of this developed gel were
evaluated in a chronic tendon rat model. The systemic
effects were analyzed direct postoperatively by G-CSF
ELISA and 6 weeks postoperatively by histological and
biomechanical testing (Figure 1).Vesicular phospholipid gel composition and in vitro
release
The preparation of VPGs by dual asymmetric centrifuga-
tion (DAC) was based on the method described by Massing
et al. [14]. In brief, the protein solution consisting of G-CSF
(Neupogen, Amgen, Thousand Oaks, CA, USA), in 10 mM
acetate buffer (pH 3.9 containing 0.004% Tween and 5%
sorbitol) was added to the lipids (Egg phosphatidylcholine
E80, Lipoid GmbH, Ludwigshafen, Germany). The mixture
was homogenized in DAC by multiple runs of 1.5 minutes
(to a total mixing time of 45 minutes) at a process speed of
3500 rpm. The samples were cooled at 2-8°C at interrupts
(after 6–10 runs) to control the temperature of the formu-
lation below 40°C.
The integrity and stability of G-CSF was analyzed by
non-reducing SDS-PAGE (sodium dodecyl sulfate poly-
acrylamide gel electrophoresis) with subsequent silver stain-
ing. In vitro release tests were conducted within flow
through cells based on the design described by Tardi et al.
[15] at 37°C. PBS (phosphate buffered saline) buffer pH 7.4
(20 mM) was used as acceptor medium. The released G-
CSF from VPGs was extracted from the release buffer by
applying DMF (N, N-Dimethylformamide) and quantified
by RP-HPLC (reversed phase high-performance liquid
chromatography).
The influence of the lipid content on the specific
release behavior of G-CSF VPGs was first investigated.
VPGs were prepared with various lipid (egg PC, LIPOID
E80) contents ranging from 400 mg/g to 490 mg/g. The
concentration of G-CSF was 4 mg/g in all these formula-
tions. In a second step, the influence of the G-CSF con-
tent on the release behavior of the system was
investigated. VPGs were prepared with various concen-
trations of G-CSF (4 mg/ml and 8.4 mg/ml). The lipid
Figure 1 Overview of the experimental set-up.
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PC, LIPOID E80) (Table 1).
For the sterile production of the VPGs the protein so-
lutions were sterile filtered and added to the previously
sterilized lipid (gamma radiated) in the sterile sample
containers (25 ml, PP) under aseptic conditions. From
that point on, aseptic production was achieved using the
hermetically sealed sample containers for the asymmet-
ric centrifugation processes. The prepared gels were then
transferred into 1 ml syringes (B. Braun Melsungen AG,
Germany) under aseptic conditions and were implanted
within 3 days after production.
Application of growth factor loaded gels in a chronic
supraspinatus tendon model
Sixty healthy (14 weeks old; 400 g) Sprague–Dawley rats
were obtained by Charles Rivers (Sulzfeld, Germany)
and included into the study. All animals received care in
compliance with the guidelines of the local animal care
committee following National of Institute of Health
guidelines. The supraspinatus tendon (SSP) was com-
pletely detached and a transosseous refixation with add-
itional VPG augmentation was performed after 3 weeks
as described before [16] (Figure 1).
In short at primary surgery the supraspinatus tendon
of the right shoulder was completely detached from its
insertion site [17]. The rats were allowed unrestricted
cage activity. For three days postoperatively the rats re-
ceived weight adapted pain medication (metamizole oralTable 1 In-vitro G-CSF Release
Formulation (1 mg) G-CSF VPGs_
Lipid content 400 mg/g
G-CSF content 4.0 mg/g
Initial release (Day 1) 64 μg
Daily release amount range 56 μg-388 μg
Average release amount per day 149 μg
Daily release percentage of the incorporated protein/% 3.7%
Daily release of G-CSF from 1 g VPGs based on various compositions.and buprenorphine subcutaneous) every 12 hours. For
repair of the chronic degenerated tendon at 3 weeks the
previous scar was re-incised and a t-shaped delta inci-
sion was performed. Applying humero-acromial exten-
sion the marking suture was retrieved and the tendon
was mobilized. All adhesions were released and the SSP
tendon was refixed transosseously according to the tech-
nique described by Thomopoulos et al. [16]. In all cases,
extensive subacromial mobilization allowed a repair
without undue tension. Footprint and tendon surface
were covered with in total 0.2 ml VPG. The 4 groups
(each n = 15) consisted of the Control (no VPG), the Pla-
cebo (VPG without G-CSF), G-CSF high (10 μg/24 hr)
and G-CSF low (1 μg/24 hr) (Figure 1). Finally the flaps
of the T-incision were refixed transosseously to the acro-
mion. The following wound closure and postoperative
treatment was performed accordingly to the first oper-
ation. All animals recovered well from both surgeries.
They were housed in cages with 4 to 6 rats and they
were followed for 6 weeks after the second surgery. Food
and water were supplied ad libitum.
Systemic concentration of G-CSF
In order to assess the protein concentration in the serum/
plasma samples, G-CSF was assayed by the enzyme-linked
immunosorbent assay (ELISA Quantikine DCS50, R&D
Systems, Minneapolis, MN, USA), designed to measure G-
CSF in cell culture supernates, serum, and plasma. It con-
tains E. coli-expressed recombinant human G-CSF and1 G-CSF VPGs_2 G-CSF VPGs_3 G-CSF VPGs_4
450 mg/g 490 mg/g 450 mg/g
4.0 mg/g 4.0 mg/g 8.4 mg/g
32 μg 43 μg 49 μg
32 μg-204 μg 32 μg-150 μg 25 μg-76 μg
88 μg 89 μg 43 μg
2.2% 2.2% 0.5%
Buchmann et al. BMC Musculoskeletal Disorders  (2015) 16:82 Page 4 of 10antibodies raised against the protein. It has been shown to
accurately quantitate recombinant human G-CSF without
obvious cross reactivity with rabbit serums [18].
Blood samples (2 μl) of the G-CSF high group (Release
rate: 10 μg/24 hr) and placebo group were taken from the
contralateral subclavian vein following short anesthesia
with Isoflurane on day 0, 2, 5 and 8. The detailed steps of
the assay followed the manual by the supplier.
Histology and immunohistochemistry
All rats were euthanized 6 weeks after the SSP reconstruc-
tion. For n = 9 in each group the musculotendinous unit
of the supraspinatus was exposed and removed proximally
from the supraspinatus fossa and distally from the bony
insertion of the humeral head for histological analysis and
stored in 4% buffered formalin solution [17]. For analysis
5 μm sections from each group and both shoulders were
stained with hematoxylin and eosin (H&E). The sections
were cut parallel to the tendon fibers. A specialized path-
ologist then evaluated the sections were then qualitatively
in a blinded fashion. Microscopy was performed on a
digital microscope (Leica Microsystems, Jena, Germany)
and image acquisition and analysis using a digital camera
system (Nikon Inc., Duesseldorf, Germany). Six high mag-
nified fields were analyzed per tendon cross-section to de-
termine the proportion of degeneration, cell number and
chronic or florid inflammation within the probes. For
evaluation of tendon degeneration a modified MOVIN
Score was used [19]. The subcategories (fiber structure,
fiber arrangement, rounding of the nuclei, regional varia-
tions in cellularity, increased vascularity and hyalinization)
were scored between 0 and 3, with 0 being normal, 1
slightly abnormal, 2 abnormal, and 3 markedly abnormal.
The results of the subcategories and the score sum were
evaluated. For immune histological assessment six high
magnified fields were analyzed per tendon cross-section to
determine the proportion of staining. A semi quantitative
score ranging from 0 (no staining) to 3 (intense staining)
was used for evaluation of treated and control shoulders.
The results of each group and inter individual differences
between treated and control shoulders were evaluated.
The contribution of collagen was described with a colla-
gen I/III quotient of the semiquantitative staining score
and compared in a sole descriptive manner.
Biomechanical testing
After scarification, the complete supraspinatus muscle
was resected from the scapula in toto in 6 rats of each
group and the humero-ulnary joint was disarticulated.
Each specimen was frozen at −18°C separately and
slowly thawed under room temperature for testing. Dur-
ing testing the thawed supraspinatus tendon was con-
stantly moistened with sprayed isotone solution of
sodium chlorid to anticipate drying out. Subsequentlythe proximal end (musculotendinous junction) was press-
fixed in a cryoclamp while the humerus was placed in a
mounting grid with bony humeral fixation (Figure 2A).
Testing was performed with the shoulder at 90° of abduc-
tion. Cooling down the cryoclamp with 5 ml of liquid
nitrogen (same amount on both sides of clamp) caused
freezing of the clamp and the musculotendinous junction
for rigid fixation, without affecting the free tendon (room
temperature). The tendons were then mounted onto a
mechanical testing machine (Zwicki 1120, Fa. Zwick)
(Figure 2B). The construct was initially set to a pre-load of
0.1 N straightening and adjustment of each tendon. A dy-
namic preconditioning in 10 cycles with a speed of
0.2 mm/min between 0.1 and 0.5 N was performed. Five
seconds after preconditioning the specimen was axially
pulled at a constant speed of 10 mm/min until maximum
load to failure [20]. Simultaneously contralateral tendons
were tested in the same way for further investigation and
percentage statistical analysis. Stiffness [N/mm] and ultim-
ate failure load [N] were calculated with SPSS software
(SPSS v12.0; SPSS, Chicago, Illinois).
Animal ethics statement
The study-protocol was approved by the local govern-
ment (Regierung von Oberbayern, Munich, Germany, N°
55.2-1-54-2531-138-07, 09.12.2009).
Statistical analysis
Between group differences (MOVIN) were compared
using Wilcoxon Test (Software R, Version 2.10.0). Stat-
istical significance was set at p ≤ 0.05. A pretesting
power-analysis (power > 0.80) was performed for the
sum score (MOVIN) with a predicted score difference
of 3 points and a SD of 2.25 points. The biomechanical
properties of the tendons were analyzed across treat-
ments with use of analysis of variance with the level of
alpha set at 0.05. Pairwise comparisons were performed
with use of two-tailed paired t tests. Statistical analysis
was performed with use of SPSS software (SPSS v12.0;
Chicago, Illinois, USA).
Results
Vesicular phospholipid gel composition and in vitro
release
No detrimental effect of the preparation process in a dual
asymmetric centrifuge on the quality of G-CSF was found
when analyzed by SDS-PAGE. The in-vitro release studies
clearly demonstrated the potential of VPGs for sustained
delivery of G-CSF. It was observed that G-CSF was re-
leased from all formulations in a linear manner following
zero-order kinetics. Increasing the lipid content from
400 mg/g to 450 mg/g resulted in a slower release rate.
However, the VPG-system appeared rather robust when
the lipid content was changed from 450 mg/g to 490 mg/g,
Figure 2 Biomechanical testing setup. A) Ball-beared mounting clamp for fixation of the cryoclamp in a mechanical testing machine (Zwicki
1120, Fa. Zwick) B) Rat supraspinatus tendon press-fixed in a cryoclamp and humerus placed in a mounting grid with bony humeral fixation for
load to failure testing.
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on 400 mg/g lipids and 4.0 mg/g G-CSF 63% of the total
entrapped protein was delivered over 408 hrs whereas
VPGs based on 450 mg/g lipids delivered 43% and VPGs
with 490 mg/g lipids delivered 35% within the same period
(Figure 3).
The release rate for the in vivo animals study had to
be adjusted. We assumed a daily release rate of a total of
1 μg/24 hours and 10 μg/24 hours per animal, respect-
ively, to be adequate for the desired biological effect. A
total volume of 200 μl of gel should be applied. With
that specification in mind, formulations with 0.2 mg/g
and 2.0 mg/g G-CSF were prepared. The average releaseFigure 3 Cumulative release of G-CSF from VPGs based on various conce
n = 3 each group).rates for the previously tested gels and the calculated,
expected release rates (over about 400 hours) for the
preclinical batches are provided in Tables 1 and 2.
The final product combined the required properties of
the daily release rate (1 μg/24 hours respectively 10 μg/
24) and the viscosity to allow to inject the gel or also to
use it arthroscopically.
Systemic concentration of G-CSF
The Quantikine G-CSF Immunoassay was validated for
the quantification of G-CSF in the serum samples. No
cross-reactivity of the assay was observed with the rat
serum. The results revealed no significant differencesntrations of lipids (egg PC, LIPOID E80) (Mean± standard deviation,
Table 2 VPG-Formulations
G-CSF
Buffer in protein solutions 10 mM acetate buffer pH 3.9
0.004% Tween
5% sorbitol
Protein concentration per ml VPGs 200 μg 2 mg
Lipid content per ml VPGs 450 mg/g
Expected release amount pro 24 h 1 μg 10 μg
Formulations of VPGs, loaded with various contents of growth factors.
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p = .440;d5 p = .307;d8 p = .219) between Placebo VPGs and
G-CSF high (10 μg/24 h) (Figure 4).Macroscopic assessment
At time of sacrifice all tendons were intact including the
transosseous suture. Between placebo and intervention
groups no macroscopic difference could be found con-
cerning hypertrophy of the tendon.Histology and immunohistochemistry
The MOVIN sum scores showed no significant differences
between all groups. Subcategory analysis revealed signifi-
cant reduction of cellularity variation for G-CSF low and
Control compared to Placebo (p = .009/p = .041). The Pla-
cebo group also showed a significant higher grade of hyali-
nization compared to control (p = .021). Detailed data is
shown in Figure 5.
For collagen I there was no significant intergroup differ-
ence. Collagen III staining revealed a significant lower level
for Placebo (p = .003) and G-CSF low (p = .035) compared
to the control group. G-CSF high showed a significant
increased Collagen III content compared to Placebo
(p = .004) and a tendency of a higher content compared to
G-CSF low (p = .053). The Collagen I/III ratio wasFigure 4 Concentration of G-CSF (pg/ml) in the rat serum (d = days po
(p > .05 for all time points).increased for G-CSF low (0.6) compared to Control (0.5),
Placebo (0.42) and G-CSF High (0.29) (Figure 6).
Biomechanical testing
Mean load to failure showed no significant differences
between treatment groups. Compared to the healthy
contralateral side all groups had a significant lower
load to failure (Placebo p = .014; G-CSF low p = .042;
G-CSF high p = .03). The load to failure ratio (treated/
contralateral) revealed a significant better restoration
of contralateral values for G-CSF low compared to
Placebo (p = .020). For G-CSF high the difference was
not significant (p = .062) (Table 3).
Measurement of stiffness revealed no significant differ-
ences between treatment groups. Compared to the
healthy contralateral side all groups except G-CSF high
had a significant lower stiffness (Placebo p = .033; G-CSF
low p = .011; G-CSF high p = .102). The stiffness failure
ratio (treated/contralateral) revealed a higher but not
significant restoration of contralateral values for G-CSF
high compared to Placebo (p = .078). For G-CSF low
there was no difference (Table 3).
Discussion
The hypothesis was proven partially as biomechanical
testing of load to failure showed significant advantages
for the G-CSF low but not for the G-CSF high group
(1 μg/24 hr). Accordingly significant differences in
immunohistology (absolute staining as well as the ratio
of Collagen I/III staining) as a marker of tendon
organization and maturation confirmed the positive ef-
fect of G-CSF low (1 μg/24 hr).
Additionally the previously described excellent bio-
compatibility of the VPGs was proven in the animal
study as the placebo group showed no consistent signifi-
cant difference in histology and biomechanics compared
to the control group [11,12]. Also the macroscopicstop.): Comparison of G-CSF high (10 μg/24 h) and Placebo VPGs
Figure 5 MOVIN-Score: Median and range of subcategories and sum score (C = control; P = Placebo; L = G-CSF low; H = G-CSF high).
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loma formation so that a usage for local applications of
drug delivery in vivo can be envisaged without risk of
negative side effects from the gel itself.
The in-vitro release studies provided clear evidence,
that VPGs are a feasible scaffold for sustained delivery of
G-CSF. G-CSF can be encapsulated by dual asymmetric
centrifugation in vesicular phospholipid matrices with-
out inducing protein destabilization. Furthermore, the
phospholipid gel (VPG) enables sustained G-CSF release.
In a wide range of formulation variables the release oc-
curs in a quasi-linear manner without burst effect which
is of particular advantage for indications that require
constant drug levels over prolonged time periods. The
desired release kinetics can be achieved by adjusting thelipid composition or the G-CSF loading amount. Both
parameters were shown to affect the matrix erosion
which in turn is the dominant mechanism controlling
protein release [13].
In current literature, a vast number of growth factors
were used in animal research on tendon repair
[13,15,21-23]. Positive effects on tendon healing were re-
ported for various GFs, but there is no clear data for a
single GF with outstanding superior characteristics. Ac-
cordingly the choice of the used growth factors was
based on data for improvement of tendon healing in
animal trials, availability, and clinical experience
[10,18,19,24-27]. One commercially available growth
factor is G-CSF, which has been shown to affect the in-
flammatory response by direct activation of neutrophile
Figure 6 Immunohistochemistry – Ratio Collagen I/Collagen III.
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taxis of mesenchymal stem cells and granulocytes and
is involved in microvessel enhancement [28,29]. In an
in vitro study Marmotti et al. [24] accelerated the out-
growth of chondrocytes which might be useful for the
reorganization of the enthesis. Previously significant
improvements of histological scores in a chronic SSP
rat model by application of G-CSF via an osmotic
pump over 20 days have been shown [10].
The application method should have a significant ef-
fect on the results of studies for biological tendon aug-
mentation, since recent data estimate the time of the
peak for physiological GF expression between week 1
and 2 after SSP refixation in animal models (rat/rabbit)
[8,9]. Respecting this knowledge a programmed release
of GF in close accordance to their physiologic release
should be aspired. Sasaki et al. [27] showed positive ef-
fects on tendon-bone integration in ACL reconstruction
(dog model) by using a continuous delivery of GCSF via
a gelatin gel.Table 3 Biomechanical testing
Group Mean load to
failure [N]
Deficit to mean contralateral
side [N]
Contralateral 34.15 ± 9.1* -
Placebo 21.40 ± 10.3 −16.78
G-CSF Low 26.19 ± 7.8 −5.68
G-CSF High 24.78 ± 6.5 −7.63
Group Mean stiffness
[N/mm]
Deficit to mean contralateral
side [N]
Contralateral 34.08 * ± 5.5 -
Placebo 18.68 ± 10.4 −20.78
G-CSF Low 16.57 ± 6.1 −17.76
G-CSF High 22.04 ± 7.0 −6.43
Load to failure (N) and Stiffness (N/mm) – mean and standard deviation (±) of abso
*Intergroup comparison showed significant differences only in comparison to the h
high .015) and stiffness (p < .01 for all groups). Treatment group comparisons showIn the previous study G-CSF was used in a dose of
5 μg/day [10]. To ensure a significant dose difference in
this study 1 and 10 μg G-CSF/day were chosen. In
current literature local application of a single dose of
5 μg G-CSF and subcutaneous injections of 0.3 to
60 μm/kg per day for systemic treatment are described
[24-27]. To our knowledge no study has been published
so far investigating dose related effects of G-CSF in
treatment of musculoskeletal disorders. The differences
between the two groups in this study (1 and 10 μg G-
CSF/day) and to the previous study (5 μg/day) might be
explained by a dose related effect with adverse effects in
a local overdose scenario. For different growth factors
e.g. b-FGF an adverse effect for higher doses with hyper-
trophic tendon healing and reduced mechanical proper-
ties is described by Fukui et al. [30].
The accuracy of the release rate transferred from
in vitro to in vivo highly depends on the local erosion
situation, in this case the subacromial space, which is
unpredictable and hard to simulate in vitro [11]. AReduced load to failure to contralateral







Reduced stiffness to contralateral







lute values and ratio to healthy contralateral side (%).
ealthy contralateral side in load to failure (Placebo .007; G-CSF low .021;G-CSF
ed non significant differences (p > .05).
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flow rate and erosion force was used as previously de-
scribed [13,15]. Together with the systemic data from
the postoperative G-CSF ELISA no conclusion can be
drawn about the actual local release rate because the re-
sults allow different interpretations. On the one hand an
isolated local effect may not affect the dosage of G-CSF
in the central-venous blood, on the other hand a local
release of only minimal amounts of G-CSF below detec-
tion limit cannot be excluded. However, a systemic influ-
ence on venous blood G-CSF levels can be excluded.
Limitations
In the current study, we performed a continuous suba-
cromial GF application, i.e. we achieved a high growth
factor dose also during the expression peaks. The manu-
facturing process of these phospholipid gels includes as
well the disadvantage that for each protein the optimal
composition (protein and lipid content) has to be tested
separately. But that also allows adaptable release rates
for different implementations. Due to the technical limi-
tations of practicable slow release gel formulations, a
physiological growth factor release profile could not be
simulated and we do not know how this influences the
tendon healing. The experiments were performed in a
small animal model, which has been used in previous
studies and shown to create a chronic supraspinatus tear,
which is comparable to the tissue found in chronic hu-
man tendon tears. According to current literature, the
rat model has been found superior to other animal
models for rotator cuff pathologies but still some restric-
tions remain (self-healing potential, fatty infiltration)
[17,31,32]. Additionally the application of 0.1 ml VPG
on the footprint and 0.1 ml VPG on the reconstructed
tendon in a small animal model involves the risk of vari-
ations of the local applied VPG volume due to differ-
ences in anatomy (size) and intraoperative bleeding.
Furthermore the in-vivo study includes only one time
point of testing after the SSP reconstruction (6 weeks
after surgery). So we have no information about the GF
effect in the early SSP healing phase and if a potential
acceleration or deceleration of the SSP early healing
phase would have occurred.
Conclusions
By use of VPGs a continuous growth factor release could
be obtained in vitro. The in vivo results demonstrate an
improvement of immunohistology and biomechanical
properties with a low dose G-CSF application via VPG.
The VPG itself was well tolerated and had no negative
influence on the healing behavior.Competing interests
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